Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study - 24/02/22
, Ankit Mittal, MBBS a, Shivdas Naik, MBBS a, Parul Kodan, DM a, Ayan Mandal, MBBS a, Ganesh Tarachand Maher, MD a, Rohit Kumar, MBBS a, Ayush Agarwal, MBBS a, Naveen R Gowda, MD b, Vikas H, MD b, Parmeshwar Kumar, MHA b, Shivam Pandey, PhD c, R M Pandey, ProfPhD c, Arvind Kumar, MD a, Animesh Ray, DM a, Pankaj Jorwal, MD a, Neeraj Nischal, MD a, Aashish Choudhary, D[ABMM] d, Megha Brijwal, MD d, Karan Madan, DM e, Rakesh Lodha, ProfMD f, Sanjeev Sinha, ProfMD a, Lalit Dar, ProfMD d, Naveet Wig, ProfMD a, Randeep Guleria, ProfMD e
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Background |
BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine that has been deployed in India. The results of the phase 3 trial have shown clinical efficacy of BBV152. We aimed to evaluate the effectiveness of BBV152 against symptomatic RT-PCR-confirmed SARS-CoV-2 infection.
Methods |
We conducted a test-negative, case-control study among employees of the All India Institute of Medical Sciences (a tertiary care hospital in New Delhi, India), who had symptoms suggestive of COVID-19 and had an RT-PCR test for SARS-CoV-2 during the peak of the second wave of the COVID-19 pandemic in India between April 15 and May 15, 2021. Cases (test-positives) and controls (test-negatives) were matched (1:1) on the basis of age and gender. The odds of vaccination with BBV152 were compared between cases and controls and adjusted for level of occupational exposure (to COVID-19), previous SARS-CoV-2 infection, and calendar time, using conditional logistic regression. The primary outcome was effectiveness of two doses of BBV152 (with the second dose received at least 14 days before testing) in reducing the odds of symptomatic RT-PCR-confirmed SARS-CoV-2 infection, expressed as (1 – odds ratio) × 100%.
Findings |
Between April 15 and May 15, 2021, 3732 individuals had an RT-PCR test. Of these, 2714 symptomatic employees had data on vaccination status, and 1068 matched case-control pairs were available for analysis. The adjusted effectiveness of BBV152 against symptomatic COVID-19 after two doses administered at least 14 days before testing was 50% (95% CI 33–62; p<0·0001). The adjusted effectiveness of two doses administered at least 28 days before testing was 46% (95% CI 22–62) and administered at least 42 days before testing was 57% (21–76). After excluding participants with previous SARS-CoV-2 infections, the adjusted effectiveness of two doses administered at least 14 days before testing was 47% (95% CI 29–61).
Interpretation |
This study shows the effectiveness of two doses of BBV152 against symptomatic COVID-19 in the context of a huge surge in cases, presumably dominated by the potentially immune-evasive delta (B.1.617.2) variant of SARS-CoV-2. Our findings support the ongoing roll-out of this vaccine to help control the spread of SARS-CoV-2, while continuing the emphasis on adherence to non-pharmacological measures.
Funding |
None.
Translation |
For the Hindi translation of the abstract see Supplementary Materials section.
Le texte complet de cet article est disponible en PDF.Plan
Vol 22 - N° 3
P. 349-356 - mars 2022 Retour au numéro
Article précédent
- Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial
- Constance Delaugerre, Frantz Foissac, Hendy Abdoul, Guillaume Masson, Laure Choupeaux, Eric Dufour, Nabil Gastli, Severine Mercier Delarue, Marie Laure Néré, Marine Minier, Audrey Gabassi, Maud Salmona, Malika Seguineau, Sarah Schmitt, Sébastien Tonglet, Alexis Olivier, Claire Poyart, Jerôme Le Goff, Xavier Lescure, Solen Kernéis, Jean-Marc Tréluyer, SPRING study group
- Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study
- Eric J Haas, John M McLaughlin, Farid Khan, Frederick J Angulo, Emilia Anis, Marc Lipsitch, Shepherd R Singer, Gabriel Mircus, Nati Brooks, Meir Smaja, Kaijie Pan, Jo Southern, David L Swerdlow, Luis Jodar, Yeheskel Levy, Sharon Alroy-Preis
Bienvenue sur EM-consulte, la référence des professionnels de santé.